{"id":"tp-35833","type":"article-newspaper","title":"Rapport Therapeutics' RAP-219 Meets Phase 2 Goals in Bipolar Mania Trial","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/35833","datePublished":"2026-10-20T17:52:15.000Z","dateModified":"2026-10-20T17:52:15.000Z","language":"en","abstract":"RAP-219 showed a 3.1-point advantage on a mania rating scale after three weeks, but 24.6% of recipients stopped treatment early.","section":"Business","references":[]}